A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine

Pharmacopsychiatry

Volumn 41, Issue 1, 2008, Pages 17-23

  Mauri, M ^a   Simoncini, M ^a   Castrogiovanni, S ^a   Iovieno, N ^a   Cecconi, D ^a   Dell'Agnello, G ^b   Quadrigli, M ^b   Rossi, A ^b   Donda, P ^b   Fagiolini, A ^c,d   Cassano, G B ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Eli Lilly Italia SpA   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZODIAZEPINE; DIAZEPAM; OLANZAPINE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH PROGRAM; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; QUALITY OF LIFE; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OBESITY; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; WEIGHT GAIN;

EID: 38849177402     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-992148     Document Type: Article

References (38)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
2. American Psychiatric Association. Releases treatment guideline for bipolar disease. Am Fam Physician 1995; 51: 1605-1609
3. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52: 967-969
4. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
5. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62: 231-238
6. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes 2006; 30: 1011-1016
7. Dalle Grave R. Perdere peso senza perdere la testa. In: Riccardo Dalle Grave: Perdere peso senza perdere la testa. Il peso ragionevole in sette passi. Positive Press 2002
8. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326
9. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005; 39: 479-486
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute for Mental Health, 1976; 218-222
11. Hugenholtz GWK, Heerdink ER, Meijer WE, Stolker J-J, Egberts ACG, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124
12. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62 (Suppl 2): 41-44
13. Kalarchian MA, Marcus MD, Levine MD, Haas GL, Greeno CG, Weissfeld LA et al. Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry 2005; 66: 1058-1063
14. Keck PE, MacElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64: 1426-1435
15. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007; 91: 169-177
16. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005; 25: 255-258
17. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-852
18. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizo-affective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry 2006; 67: 547-553
19. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, MacEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
20. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnsson CG. The effects of and educational intervention of antipsychotic-induced weight gain. J Nurs Scholarsh 2003; 35: 237-241
21. Matthews DR, Hosker JP, Rudenski AS, Taylor BA, Treacher DF, Turner R. Homeostasis model assessment insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
22. McIntyre RS, MacCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-281
23. Mithat B, Alpaslan T, Bulent C, Cengiz T. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium. Pharmacopsychiatry 2005; 38: 105-106
24. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14: 278-282
25. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93
26. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar 1 affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26
27. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087
28. Scocco P, Longo R, Caon F. Weight change in treatment with olanzapine and a psychoeducational approach. Eat Behav 2006; 7: 115-124
29. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91-96
30. Sowell MO, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003; 88: 5875-5880
31. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002; 87: 2918-2923
32. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003; 23 (Suppl 1): S21-26
33. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-211
34. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979; 28: 1086-1096
35. United States Department of Agriculture and United States Department of Health and Human Services. Dietary Guidelines for Americans 2000, Home and Garden Bulletin No. 232, 5th edn. 2000. U.S. Government Printing Office Washington, DC
36. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24: 59-73
37. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-1155
38. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007; 27: 246-251